Showing posts with label xenotransplantation. Show all posts
Showing posts with label xenotransplantation. Show all posts

Thursday, September 17, 2026

Scientists grow human brain tissue inside a live mice skull

Amazing stuff!

"... a group from Stanford University has found a way to advance their usefulness for studying brain development and disease — by instead growing [organoids] inside mice that have had large parts of their own brains genetically removed. 

Neuroscientists say these “neuro-chimeric” mice, whose brains are half-human — by volume, not by number of neurons — are an important innovation for a field hampered by longstanding challenges in accessing human brain tissue for research. But such models also raise a host of ethical questions that will get thornier the more advanced they become. ..."

"... researchers succeeded in transplanting self-organizing bits of laboratory-grown human brain tissue called cortical organoids into mice specially bioengineered and bred so that almost all of their cerebral cortex was missing. (The cerebral cortex is the outermost “rind” of the brain, to which much of our higher-level functioning such as cognition, language, attention and decision-making is attributed.)

The resulting vastly enlarged cavity in the mice’s brains proved to be a hospitable environment. The human tissue survived, thrived, grew — and developed working connections to the mice’s brain and beyond to the spinal cord. ...

The new methodology should speed research into the underlying biological causes of schizophrenia, epilepsy, profound autism and cerebral palsy ..."

From the abstract:
"The inaccessibility of human brain tissue limits the study of human development and function, a challenge that human stem-cell-derived neural models are beginning to address.
Transplantation of neural organoids into rodent hosts enables the in vivo study of aspects of human neurodevelopment and circuit function, alongside behavioural phenotyping of the host animals. However, spatial limitations and competition with host circuits constrain the integration of neural organoids, which is critical for studying disease.
Here we establish a transplantation platform using a genetic strategy to effectively deplete glutamatergic neurons from mouse neocortex and hippocampus (apallial) and neonatally engraft the cortical cavity with human stem-cell-derived cortical organoids (hCO) to generate xenocortical mice.
This leads to robust graft growth with hCOs occupying most of the cortical volume and generating a diversity of human cortical cell types, including layer 5 extratelencephalic projection neurons.
Human cortical neurons integrate with the mouse nervous system, and in vivo cortical graft-wide calcium imaging and electrophysiological analyses revealed patterns of organized activity resembling developing circuits.
Behavioural analyses of apallial and xenocortical mice revealed broadly preserved locomotion alongside selective differences in limb coordination and altered organization of spontaneous behaviour.
Lastly, this platform enabled behavioural readouts in a model of injury to developing human cortical cells. We envision that xenocortication will be useful for obtaining circuit- and behaviour-level readouts using human neurons to study neurodevelopment, model disease and develop therapeutics."

Scientists grow human brain tissue inside mice. Here's why | STAT "Advance opens new ways to studying brain development and disease, but raises ethical concerns"

Stanford Medicine team creates advanced model for studying brain development, disorders "The ability to study brain disorders that arise before birth has taken a leap forward as Stanford Medicine researchers find a new way to grow human brain tissue outside of the human brain."



Fig. 1: Characterization of the apallial mouse model.


Fig. 2: Transplantation of human cortical organoids into the apallial mouse.


Sunday, October 12, 2025

Chinese Surgeons Perform First Pig-to-Human Liver Transplant

Good news!

"“Surgeons in China have for the first time transplanted a section of liver extracted from a genetically modified pig into a human cancer patient ...

The surgeons, who described the procedure in a paper in The Journal of Hepatology, grafted the portion of pig liver onto the left lobe of a 71-year-old patient’s liver after removing the larger right lobe, where a tumor the size of a grapefruit had grown. The lobe with the porcine transplant functioned, producing bile and synthesizing blood clotting factors, the surgeons reported. The patient’s body did not reject the organ graft, which enabled the remaining left lobe of the patient’s own liver to regenerate and grow, the scientists said.

The porcine liver lobe was removed 38 days after the transplant, when complications developed, the surgeons wrote in the report. The patient, who had advanced disease, died a little over five and a half months later. ..."

From the highlights and abstract:
"Highlights
• First successful auxiliary porcine liver xenotransplantation from a 10-gene edited pig to a living recipient, distinct from prior brain-dead recipient cases.
• Porcine albumin and coagulation factors were bioactive, sustaining hepatic metabolic function without allergic reactions or other adverse effects.
• Early postoperative course showed no hyperacute or acute rejection, supporting the effectiveness of donor gene editing and immunosuppression.
• Xenotransplantation-associated thrombotic microangiopathy (xTMA) was successfully controlled by graft removal, followed by eculizumab and plasma exchange.
• Establishes auxiliary liver xenotransplantation as a life-saving bridge for unresectable liver cancer or liver failure, and provides a clinical paradigm for future liver xenotransplantation trials.

Abstract
Background
The advent of genetically edited porcine-to-human xenotransplantation has predominantly focused on cardiac and renal applications, with no reported cases of porcine-to-human liver xenotransplantation. This study presents the world’s first successful genetically modified pig auxiliary liver xenotransplantation in a living human, achieving an unprecedented survival of 171 days, and provides valuable insights into the critical factors influencing the procedure’s success.

Methods
A genetically modified pig liver, incorporating 10 targeted gene edits, was transplanted as an auxiliary organ into a patient with large hepatocellular carcinoma in the right hepatic lobe, which was initially deemed ineligible for curative resection. Liver function, metabolic, and coagulation markers were closely monitored throughout the perioperative period.

Results
For the first 31 days post-transplant, no hyperacute or acute rejection, infections, or significant complications were observed, and the patient’s hepatic and renal functions remained stable.
Early postoperative coagulopathy, as indicated by elevated D-dimer and fibrin degradation products, was successfully managed through anticoagulant therapy. However, on postoperative day 38, the auxiliary liver was removed due to xenotransplantation-associated thrombotic microangiopathy (xTMA). Subsequent management with eculizumab and plasma exchange successfully resolved the xTMA. Unfortunately, repeated upper gastrointestinal hemorrhage ultimately led to the patient's death on day 171.

Conclusions
This study demonstrates the feasibility of auxiliary porcine liver xenotransplantation as a bridging approach to human to liver transplantation. Postoperative xTMA presents a significant challenge to long-term success, highlighting the need for further research to improve xenotransplantation outcomes.

Impact and implications
This study reports the world’s first auxiliary xenotransplantation from a 10-gene-edited pig to a living human recipient - distinct from previous studies involving brain-dead donors.
The donor liver was engineered using a 10-gene editing platform, including the knockout of xenoantigen genes and the knock-in of seven human transgenes for immune and coagulation compatibility - pushing the boundaries of synthetic biology in clinical transplantation.
The porcine graft exhibited metabolically active liver function, bile secretion, and coagulation correction, demonstrating not only survival but clinically meaningful function.
Our work documents, for the first time, xenotransplantation-associated thrombotic microangiopathy (xTMA) in a living human recipient, with comprehensive immunological and histopathological analysis - critical knowledge for the field."

Chinese Surgeons Perform First Pig-to-Human Liver Transplant - Human Progress



Graphical abstract


Friday, September 05, 2025

Molecular Signatures Reveal Delayed Pig Organ Rejection after Xenotransplantation

Update: Just realized that the research article is quite outdated, published in September 2023, but the popular science article is new.

Bad news! However, I bet this issue will be overcome soon! Hopefully, sooner than later we will not have to rely on pigs anymore.

"... “Xenotransplantation could provide an unlimited and renewable source of organs,” ...

Over the past few years, the science of xenotransplantation has greatly advanced because scientists managed to prevent hyperacute organ rejection using genetically modified pigs. But ... recently found that humans still react to pig organs—these responses are just subtler and delayed. ..."

"... The study ... delved into the patients’ immune responses and revealed a unique form of rejection mediated by antibodies. Despite initial success, these findings underscore the need for a deeper understanding of the immune interactions between humans and pig organs in xenotransplantation.

The innovative approach employed advanced immunology and molecular microscopy technologies to precisely characterize immune cells within the transplanted organs. The results revealed a distinctive rejection pattern involving innate immune cells, a type of immunity shared across species, expressing genes typical of human organ rejection mediated by antibodies.

While this form of rejection poses challenges, it also provides valuable insights. Researchers can now identify molecular targets to optimize genetically modified pig models and develop immunosuppressive treatments. Existing treatments for antibody-mediated rejection in human transplantation may also be adapted for xenotransplantation. ..."

From the abstract:
"Summary
Background
Cross-species immunological incompatibilities have hampered pig-to-human xenotransplantation, but porcine genome engineering recently enabled the first successful experiments. However, little is known about the immune response after the transplantation of pig kidneys to human recipients. We aimed to precisely characterise the early immune responses to the xenotransplantation using a multimodal deep phenotyping approach.

Methods
We did a complete phenotyping of two pig kidney xenografts transplanted to decedent humans. We used a multimodal strategy combining morphological evaluation, immunophenotyping (IgM, IgG, C4d, CD68, CD15, NKp46, CD3, CD20, and von Willebrand factor), gene expression profiling, and whole-transcriptome digital spatial profiling and cell deconvolution. Xenografts before implantation, wild-type pig kidney autografts, as well as wild-type, non-transplanted pig kidneys with and without ischaemia-reperfusion were used as controls.

Findings
The data collected from xenografts suggested early signs of antibody-mediated rejection, characterised by microvascular inflammation with immune deposits, endothelial cell activation, and positive xenoreactive crossmatches. Capillary inflammation was mainly composed of intravascular CD68+ and CD15+ innate immune cells, as well as NKp46+ cells.
Both xenografts showed increased expression of genes biologically related to a humoral response, including monocyte and macrophage activation, natural killer cell burden, endothelial activation, complement activation, and T-cell development. Whole-transcriptome digital spatial profiling showed that antibody-mediated injury was mainly located in the glomeruli of the xenografts, with significant enrichment of transcripts associated with monocytes, macrophages, neutrophils, and natural killer cells. This phenotype was not observed in control pig kidney autografts or in ischaemia-reperfusion models.

Interpretation
Despite favourable short-term outcomes and absence of hyperacute injuries, our findings suggest that antibody-mediated rejection in pig-to-human kidney xenografts might be occurring. Our results suggest specific therapeutic targets towards the humoral arm of rejection to improve xenotransplantation results."

Molecular Signatures Reveal Delayed Pig Organ Rejection | The Scientist "Genetically modified pigs have led to a breakthrough in xenotransplantation, but it didn’t eliminate all possibilities of organ rejection."

Immune response after pig-to-human xenotransplantation: a multimodal phenotyping study (original news release) "In a groundbreaking study ... has achieved a major breakthrough in the field of xenotransplantation."

Friday, April 11, 2025

Longest human transplant of pig kidney fails after only 4 months

Bad news, but no reason to despair!

"Towana Looney, a 53-year-old grandmother from Alabama who received a kidney from a gene-edited pig on 25 November 2024, had it removed last week after the organ suddenly stopped functioning. The 4 months and 9 days Looney spent with the kidney set a new record for a pig organ in a human, but it is yet another setback for the long-struggling field known as xenotransplantation."

Wednesday, April 09, 2025

Australia on the verge of diabetes treatment breakthrough

Good news!

"Australian researchers are taking the final steps towards being the first in the world to take pancreatic islet cells from genetically modified pigs and transplant them into human patients. Their goal: to cure type 1 diabetes (T1D).

The culmination of decades of work ...

“We’ve got animals surviving out past 2 years post-transplant, with no hyperacute rejection, no rejection, and with cured diabetes in that pre-clinical model. ..."

Australia on the verge of diabetes breakthrough


Human islets (red) sourced from a cadaveric human pancreas donor.


Thursday, March 27, 2025

First genetically modified pig liver xenotransplantation (into a brain-dead human recipient)

Good news!

What are the ethical considerations when a brain-dead human recipient is involved? Was that necessary?

"Researchers in China say they performed the first transplant of a genetically modified pig liver into a brain-dead human recipient ...

The recent transplant was carried out on 10 March 2024 at Xijing Hospital of Fourth Military Medical University in China.

The researchers say once in place, the organ secreted bile and produced porcine albumin, part of the process a normal functional liver performs. ...

Why test brain-dead patients?

Hawthorne [Dr Wayne Hawthorne, Immediate Past President of the International Xenotransplantation Association (IXA)] says that its safer, in some ways, to test xenotransplantation in a deceased patient before proceeding to a live recipient.

It gives surgeons the ability to take large biopsies and many samples from the organ and the recipient over a short period of time, which they cannot necessarily do in a live recipient who will recover. ..."


From the abstract:
"The shortage of donors is a major challenge for transplantation; however, organs from genetically modified pigs can serve as ideal supplements. Until now, porcine hearts and kidneys have been successively transplanted into humans.
In this study, heterotopic auxiliary transplantation was used to donate a six-gene-edited pig liver to a brain-dead recipient.
The graft function, haemodynamics, and immune and inflammatory responses of the recipient were monitored over the subsequent 10 days. Two hours after portal vein reperfusion of the xenograft, goldish bile was produced, increasing to 66.5 ml by postoperative day 10. Porcine liver-derived albumin also increased after surgery. Alanine aminotransferase levels remained in the normal range, while aspartate aminotransferase levels increased on postoperative day 1 and then rapidly declined. Blood flow velocity in the porcine hepatic artery and portal and hepatic veins remained at an acceptable level. Although platelet numbers decreased early after surgery, they ultimately returned to normal levels. Histological analyses showed that the porcine liver regenerated capably with no signs of rejection. T cell activity was inhibited by anti-thymocyte globulin administration, and B cell activation increased 3 days after surgery and was then inhibited by rituximab. There were no significant peri-operative changes in immunoglobulin G or immunoglobulin M levels. C-reactive protein and procalcitonin levels were initially elevated and then quickly declined. The xenograft remained functional until study completion."

First pig-to-human liver xenotransplantation



Extended Data Fig. 2: The heterotopic auxiliary liver xenotransplantation procedure.


Saturday, February 08, 2025

First clinical trial for genetically modified pig-organ transplants for patients with end-stage renal disease

Good news!

"The US Food and Drug Administration has cleared biotech firm United Therapeutics to begin the first clinical trial transplanting genetically modified pig organs into humans. The company, which has engineered pigs with ten genetic edits that help the organs evade the human immune system, has already transplanted several kidneys and hearts into individuals on a case-by-case basis. Its new trial aims to transplant pig kidneys into up to 50 people with end-stage renal disease. United Therapeutics’ competitor, eGenesis, plans to ask the FDA to approve another clinical trial using pig organs later this year."

"The first clinical trial testing whether pig kidneys can be safely transplanted into living people has been approved by the US Food and Drug Administration (FDA). As part of the trial, which will begin later this year, kidneys from genetically modified pigs will be transplanted into people with chronic kidney disease whose organs no longer function independently. ..."

Nature Briefing: Translational Research

The science behind the first pig-organ transplant trial in humans "The small trial will help to establish whether kidneys from genetically modified pigs can be transplanted into people safely and effectively."



Surgeons at Massachusetts General Hospital in Boston transplanted a modified pig kidney into a living person for the first time in 2024.


Sunday, October 02, 2022

Israeli scientists discover how to make elderly human skin young again

Good news! Botox move over! Unfortunately, this research is still early stage.

"... Using an old skin graft on young mice, they proved that it is possible to make skin and other organs young again via a change in molecular structure through all the layers of the skin. ...
Transplanting aged human skin onto young mice with severe combined immunodeficiency disease (SCID) that genetically affects both B and T lymphocytes can rejuvenate the transplantation of living cells, tissues or organs from one species to another, they wrote. This is accompanied by angiogenesis (the growth of new blood vessels), repigmentation of the epidermis (outer layer of the skin) and significant improvements in vital biomarkers connected to aging. ..."

From the abstract:
"Transplanting aged human skin onto young SCID/beige mice morphologically rejuvenates the xenotransplants. This is accompanied by angiogenesis, epidermal repigmentation, and substantial improvements in key aging-associated biomarkers, including ß-galactosidase, p16ink4a, SIRT1, PGC1α, collagen 17A, and MMP1. Angiogenesis- and hypoxia-related pathways, namely, vascular endothelial growth factor A (VEGF-A) and HIF1A, are most up-regulated in rejuvenated human skin. This rejuvenation cascade, which can be prevented by VEGF-A–neutralizing antibodies, appears to be initiated by murine VEGF-A, which then up-regulates VEGF-A expression/secretion within aged human skin. While intradermally injected VEGF-loaded nanoparticles suffice to induce a molecular rejuvenation signature in aged human skin on old mice, VEGF-A treatment improves key aging parameters also in isolated, organ-cultured aged human skin, i.e., in the absence of functional skin vasculature, neural, or murine host inputs. This identifies VEGF-A as the first pharmacologically pliable master pathway for human organ rejuvenation in vivo and demonstrates the potential of our humanized mouse model for clinically relevant aging research."

Israeli scientists discover how to make elderly human skin young again - The Jerusalem Post After 20 years of research, Haifa scientists claim to have found the way to make elderly human skin young again – in lab rodents.




Monday, July 11, 2022

Clinical trials for pig-to-human organ transplants inch closer in the U.S.

Good news! Human volunteers please sign up!

Why does the U.S. FDA even have power over an organ transplant performed in one of the states? Strikes me clearly as too much federal power over the internal affairs of individual states!!! SCOTUS are you listening?

"... Researchers have repeatedly transplanted pig organs into non-human primates, such as baboons, with success. But these experiments don’t simulate human trials perfectly. ...
Physicians see an urgent need for the [human] trials: more than 100,000 people are waiting for organ transplants in the United States alone. ...
In late 2021, for instance, surgeons transferred genetically modified pig kidneys into two legally dead people who had no discernible brain function and were on ventilators. [Was any consent given by survivors etc.?] The kidneys functioned normally over the 54 hours of the test and seemed to produce urine. ...
In January this year, a severely ill man became the first to receive a pig heart, during an operation in Baltimore, Maryland. (The man otherwise faced certain death, so the FDA granted a compassionate-use authorization for the procedure.) ..."

Clinical trials for pig-to-human organ transplants inch closer US regulatory agency signals willingness to allow first xenotransplant trials.

Monday, May 23, 2022

First pig kidneys transplanted into two humans: what scientists think

Kidney failures has been a very serious medical issue for decades, but does it justify desperate measures. 

"In 2018, 785,883 Americans had kidney failure, and needed dialysis or a kidney transplant to survive (2 in every 1,000 people). 554,038 of these patients received dialysis to replace kidney function and 229,887 lived with a kidney transplant." (Source)

The story about these xenotransplants is a little bit bizarre! This story does not exactly instill confidence in medicine and its practitioners!

These two cases of kidney xenotranspantations raises some serious ethical questions! We do not even learn whether these two patients previously consented to this kind of treatment. We only have to assume.

The two patients, who received the kidney Xenotransplant, were legally dead at the time?

Exactly how long did these two patients survive? Where these two patients monitored for the whole time?

Apparently, up to 54 hours after the xenotransplant was performed things worked out quite well, but what happened after?

"... In their transplant tests, which they performed in September and November 2021, Montgomery and his colleagues used pigs that had been genetically engineered to lack a gene for a protein called alpha-1,3-galactosyltransferase (αGal). The pig version of αGal triggers the human immune system to reject xenotransplants (organs transferred from a different species). With each kidney that the researchers transplanted, they also transplanted a pig thymus, an organ that produces immune cells and helps the body accept the foreign organs.

They tested these “thymokidneys” in two people who had been declared legally dead one to two days earlier because they did not have brain function. ..."

From the abstract:
"... CONCLUSIONS
Genetically modified kidney xenografts from pigs remained viable and functioning in brain-dead human recipients for 54 hours, without signs of hyperacute rejection. (Funded by Lung Biotechnology.)"

First pig kidneys transplanted into people: what scientists think The genetically modified organs seemed to function for more than two days but some researchers are sceptical that the experiments had value.

Tuesday, January 11, 2022

Matricelf treats pig's spinal cord injury with human implants


Xenotransplantation in both directions at about the same time!

"Israeli biotech company Matricelf (TASE: MTLF) today reported that it has successfully completed another usability trial with human implants for replacing the injured spinal cord of a living pig. The company is developing autologous (bone marrow) implants for the regeneration of damaged tissues by using stem cells and external stem cell components from the patients themselves.

Conducting the trial in the live pig simulates the anticipated surgical procedure in humans, both in terms of the flow of brain and spinal fluids (cerebrospinal fluid - CSF) and in terms of the bleeding that might be created near the site of the injury. During the trial, the company was successful in positioning, by two neurosurgeons, human implants (that is to say neural implants originating from human tissues) developed by the company, in the injured spinal cord of the living pig. After the placement of the implants in the area of the injury, a substitute Dura Patch was grafted into the injured spinal cord, as is done with humans, the membranes surrounding the spinal cord were sutured back together, and the trial was completed with major success. ..."

Matricelf treats pig's spinal cord injury with human implants - Globes The company is developing implants for the regeneration of damaged tissues by using stem cells from the patients themselves.

Monday, July 05, 2021

Chinese Scientists Produce Genetically Modified Pigs for Human Transplant

Good news! Successful porcine xenotranplantation is coming another step or more closer! Lucky pig charm!

This research is not the latest. First published December 2019 as a preprint, then published September 2020 in Nature Biomedical Engineering. U.S. based companies and scientists were also involved.

"eGenesis [Cambridge, Massachusetts] is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis." (Source)

"... Xinhua reported that the team of Yang Luhan, founder of Qihan Biotech in Hanzhou, China, and cofounder and chief scientist of Cambridge gene-editing company eGenesis in Boston, had created a prototype xenograft with clinical potential, successfully solving two major xenograft safety challenges: removing porcine endogenous retroviruses from pigs and enhancing xenograft immunocompatibility. ...
In 2017, eGenesis announced that it had produced the world’s first genetically modified pigs that do not carry endogenous retroviruses, eliminating the risk of virus transmission from pigs to humans; and in 2018, eGenesis produced the first immunoplex-engineered pig, reducing the immune rejection of pig allogeneic organ transplants. ..."

"Xenotransplantation, specifically the use of porcine organs for human transplantation, has long been sought after as an alternative for patients suffering from organ failure. However, clinical application of this approach has been impeded by two main hurdles: 1) risk of transmission of porcine endogenous retroviruses (PERVs) and 2) molecular incompatibilities between donor pigs and humans which culminate in rejection of the graft. ...
In this study, we improved the scale of porcine germline editing from targeting a single repetitive locus with CRISPR to engineering 13 different genes using multiple genome engineering methods. ..."

Chinese Scientists Produce Genetically Modified Pigs for Human Transplant (behind paywall)




Sunday, December 20, 2020

FDA approves genetically altering pigs, potentially for drugs or transplants

Good news! This is only the beginning! More to come!

"Genetically engineering pigs so they lack a certain sugar on the surface of their cells that triggers meat allergies or organ rejection won approval from the Food and Drug Administration Monday. The regulatory clearance — the first of an intentional genomic alteration in a product with both food and medical uses — means the animals could be safer sources of not just food but also treatments such as the blood-thinner heparin. ...
GalSafe pigs, named for their lack of detectable alpha-gal sugar, could potentially provide tissues and organs for patients without the danger of rejection caused by the presence of the sugar in cross-species procedures known as xenografts or xenotransplantation. ..."

FDA approves genetically altering pigs, potentially for drugs or transplants